Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenmai Baofei Fang is a Traditional Chinese Medicine (TCM) herbal formula primarily utilized for the treatment of chronic respiratory diseases, most notably Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis. The formula is an evolution of the classical Shenmai San, traditionally composed of *Panax ginseng* and *Ophiopogon japonicus*, which are intended to tonify Qi and nourish Yin. Shenmai Baofei Fang is specifically designed to address the 'Qi and Yin deficiency' pattern in TCM, aiming to improve lung function, reduce systemic and local airway inflammation, and alleviate clinical symptoms such as dyspnea and chronic cough. Research indicates that the formula may exert its therapeutic effects by modulating inflammatory cytokines and inhibiting fibrotic signaling pathways in lung tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenmai Baofei Fang.